Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Fish and Richardson
Boehringer Ingelheim
QuintilesIMS
Fuji
Deloitte
Julphar
Chinese Patent Office
AstraZeneca

Generated: December 16, 2018

DrugPatentWatch Database Preview

DUEXIS Drug Profile

« Back to Dashboard

Which patents cover Duexis, and when can generic versions of Duexis launch?

Duexis is a drug marketed by Horizon and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-four patent family members in fourteen countries.

The generic ingredient in DUEXIS is famotidine; ibuprofen. There are eighteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the famotidine; ibuprofen profile page.

Drug patent expirations by year for DUEXIS
Generic Entry Opportunity Date for DUEXIS
Generic Entry Date for DUEXIS*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for DUEXIS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Horizon DUEXIS famotidine; ibuprofen TABLET;ORAL 022519-001 Apr 23, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Horizon DUEXIS famotidine; ibuprofen TABLET;ORAL 022519-001 Apr 23, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Horizon DUEXIS famotidine; ibuprofen TABLET;ORAL 022519-001 Apr 23, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Horizon DUEXIS famotidine; ibuprofen TABLET;ORAL 022519-001 Apr 23, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for DUEXIS
Drugname Dosage Strength RLD Date
➤ Subscribe Tablets 800 mg/26.6 mg ➤ Subscribe ➤ Sign Up

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Fish and Richardson
Boehringer Ingelheim
QuintilesIMS
Fuji
Deloitte
Julphar
Chinese Patent Office
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.